Immunotherapy for Castration-Resistant Prostate Cancer

Quote

Anonymous

Guest
Peer Exchange
Published Online: Tuesday, September 18, 2012
Print
Email
Great video discussion on first-line foundation of care use of Provenge from Urology Key Opinion Leaders:

http://www.onclive.com/peer-exchange/prostate/Immunotherapy-for-Castration-Resistant-Prostate-Cancer

Peer Exchange
Published Online: Tuesday, September 18, 2012

The role of immunotherapy for men with castration-resistant prostate cancer (CRPC) is an area that has garnered a great deal of discussion among physicians. E. David Crawford, MD, agrees with the NCCN guidelines, which suggest that sipuleucel-T (Provenge) should be the first-line choice for minimally or asymptomatic CRPC.

Crawford foresees a large paradigm shift in the future for urologists treating CRPC. Multiple new therapeutics, which are easily given by urologists, are rapidly becoming available, such as the immunotherapy sipuleucel-T and the investigational agent radium-223, which Crawford describes as a game changer. Recently approved agents include abiraterone acetate and enzalutamide with TAK-700 (orteronel) and lyase inhibitors rapidly approaching in the development pipeline.

The many different mechanisms of actions for these agents make combinations a viable option.
 






The role of immunotherapy for men with castration-resistant prostate cancer (CRPC) is an area that has garnered a great deal of discussion among physicians. E. David Crawford, MD, agrees with the NCCN guidelines, which suggest that sipuleucel-T (Provenge) should be the first-line choice for minimally or asymptomatic CRPC.[/QUOTE]

It is interesting that Warren Buffet's doctors didn't find one iota of potential benefit for him. One would think that it couldn't hurt to take PV early and for different labels than just CPRC, but his doctors apparently had no interest. It wasn't about money. We all know Warren could have paid for it himself.
 






1 out of 6 men are diagnosed with prostate cancer during their lifetime. Their are 2.5 million men in this country that have been diagnosed with prostate cancer. The vast majority are cured with either having the prostate removed or by radiation treatment. Buffet's was caught very early and it is nearly 100% odds that he was cured by the radiation treatment. Why would Buffet's doctors adminster Provenge to him when he was cured by the radiation. If you had heart disease would you want your doctor to give you a heart bypass operation when heart medications would cure you. Here are some prostate cancer stats for yor review:

http://seer.cancer.gov/statfacts/html/prost.html#survival

Your response above clearly demonstrates your complete ignorance on the topic (as is a common theme of all your posts).
 






Wealthy man would turn 97% to 99% if PV would have done that. Putting Sipucel-T into your blood is different than having a heart bypass operation. Once again, the analogies are deceptive and flawed just for an agenda.
 






Anonymous said:
The role of immunotherapy for men with castration-resistant prostate cancer (CRPC) is an area that has garnered a great deal of discussion among physicians. E. David Crawford, MD, agrees with the NCCN guidelines, which suggest that sipuleucel-T (Provenge) should be the first-line choice for minimally or asymptomatic CRPC.
Click to expand...

It is interesting that Warren Buffet's doctors didn't find one iota of potential benefit for him. One would think that it couldn't hurt to take PV early and for different labels than just CPRC, but his doctors apparently had no interest. It wasn't about money. We all know Warren could have paid for it himself.[/QUOTE]

Provenge is perfect for a specific group. Because of this, it would be a great niche product for BP who could then use the science and build it into a true vaccine therapy. Everything points to a takeover because of the balance sheet problems, a need to raise cash in an environment that will not make it possible, a dilution would not work for shareholders, JP Morgans impending presence and weight in determining the future of the company, and the potential huge liablity of both federal cases and class action cases. Directors and Officers Insurance would not cover crimes.
 












Again you show your complete ignorance on the treatment of prostate cancer. Your short the stock agenda is clear. Why would Buffet's opt for Provenge when he was cured by radiation treatment? Surgery or radiation treatment is curative for the large majority of prostate cancer patients, period. Your claims lack basic common sense.

It is similar to when your doctor treats your condition with a labotomy so as to render you totally comatose. Does he then follow with electric shock treatment, when for your own safety and that of society in general, you were already rendered comatose? Over medical treatment serves no purpose.
 






Thanks for posting the highly favorable Provenge comments by Dr. Crawford where he stated: " E. David Crawford, MD, agrees with the NCCN guidelines, which suggest that sipuleucel-T (Provenge) should be the first-line choice for minimally or asymptomatic CRPC."

This is major good news for Dendreon.

http://www.edavidcrawford.com/drupal/

Dr. Crawford is an internationally recognized expert in prostate cancer, benign prostate hypertrophy (BPH) and other urologic cancers.

Dr. Crawford is the distinguished Professor of Surgery, Urology, and Radiation Oncology, and head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus. He is an active clinician, researcher, and teacher. He has been recognized as one of the Best Doctors in America, one of the Best Cancer Doctors, one of the Top 20 Urologists in the county by Men's Health Magazine, and recently selected as the Healthcare Provider of the Year in the Denver Metro Area by The Denver Business Journal. In addition, he is the recipient of more than 95 research grants in the diagnosis and treatment of prostate cancer, metastatic prostate cancer, hormone refractory prostate cancer, benign prostatic hyperplasia (BPH), advanced bladder cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 600 published articles, contributed to nearly 100 educational books and provided thousands of educational talks for patients and physicians. In an effort to raise awareness and education about prostate health, Dr. Crawford also founded and chairs a 501c3 non-profit called the Prostate Conditions Education Council.
 






Thanks for posting as well. The Urology Key Opinion Leaders are certainly become Provenge supporters. So refreshing after reading all the wild false and unsupported allegations posted by the sociopath.
 






Anonymous said:
Thanks for posting as well. The Urology Key Opinion Leaders are certainly become Provenge supporters. So refreshing after reading all the wild false and unsupported allegations posted by the sociopath.
Click to expand...

There is some sociopath who keeps claiming that the stock has gone from $75 to $3. Those are lies. The stock only got to $57 and it's had a recent low of $4.05, not "in the $3s".

Get a life, stop shorting the stock so we can pump it again.
 












Anonymous said:
Again you show your complete ignorance on the treatment of prostate cancer. Your short the stock agenda is clear. Why would Buffet's opt for Provenge when he was cured by radiation treatment? Surgery or radiation treatment is curative for the large majority of prostate cancer patients, period. Your claims lack basic common sense.
Click to expand...

I hear Thompson is leaving. This could have more bad implications.
 


















Top Bottom
Back
Quote